U.S. Army Medical Materiel Development Activity (USAMMDA) logo
U.S. Army Medical Materiel Development Activity

Post-Traumatic Stress Disorder Drug Treatment Adaptive Platform Trial

PTSD pharmacy

Description: FDA approval of a new drug indication for treatment of PTSD, and/or to improve Level-of-Evidence knowledge used to inform clinicians in decisions for off-label use of FDA-licensed drugs.

Requirement: U.S. forces are deployed to operational regions where there is significant risk of combat exposure, which may result in the development of PTSD symptoms. In total, more than 400,000 service members and Veterans have qualified for PTSD disability benefits, and an estimated additional 150,000 to 200,000 may be eligible.

Last Modified Date: 06/27/2024